^
    Back
    Association details:
    Biomarker:MET overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug:Haiyitan (gumarontinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate the Safety and Anti-tumor Activity of SCC244

    Excerpt:
    ...In Phase Ia, histologically confirmed NSCLC (including sarcomatoid carcinoma) with c-Met alterations defined as c-Met gene amplification ≥ 5 copies or c-Met protein overexpression (IHC 3+) or c-Met exon 14 skipping mutation....
    Trial ID:
    NCT03466268
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Asia 2022
    Title:

    313P - A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpression

    Published date:
    11/28/2022
    Excerpt:
    SCC244 demonstrated promising anti-tumor activity with durable response across treatment lines in NSCLC patients with MET overexpression.
    Trial ID:
    GLORY; NCT03457532
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2020
    Title:

    A phase I clinical trial to assess the safety, pharmacokinetics, and antitumor activity of glumetinib (SCC244) in patients with advanced non-small cell lung cancers (NSCLCs).

    Published date:
    05/28/2020
    Excerpt:
    Glumetinib was well tolerated at doses up to 400 mg once daily and demonstrated clinical activity in advanced NSCLC with MET alterations….one patient with MET overexpression at 200mg dose level had a best of response of partial response and completed 44 weeks glumetinib treatment...
    DOI:
    10.1200/JCO.2020.38.15_suppl.e21702
    Trial ID:
    NCT03466268